Edition:
United States

Bayer AG (BAYGn.DE)

BAYGn.DE on Xetra

108.05EUR
4:10am EDT
Change (% chg)

€2.85 (+2.71%)
Prev Close
€105.20
Open
€107.25
Day's High
€108.50
Day's Low
€106.95
Volume
719,929
Avg. Vol
1,872,889
52-wk High
€112.00
52-wk Low
€83.45

Latest Key Developments (Source: Significant Developments)

Crispr Therapeutics, Casebia Therapeutics announce exclusive development and option agreement with Stridebio
Monday, 17 Apr 2017 08:00am EDT 

April 17 (Reuters) - Crispr Therapeutics Ag :Crispr Therapeutics and Casebia Therapeutics announce exclusive development and option agreement with Stridebio.Crispr Therapeutics - under agreement, Stridebio will use proprietary platform to develop AAV vectors with improved properties.Crispr Therapeutics - co, Casebia will have option to exclusively license aav vectors with desired properties for use in their in Vivo gene-editing programs.Stridebio will receive development funding, milestones and royalties on licensed vectors.Stridebio will retain certain rights to use Novel aav vectors for gene therapy applications.  Full Article

Oncomed Pharmaceuticals announces Bayer terminates its option to license vantictumab or ipafricept
Monday, 10 Apr 2017 08:02am EDT 

Oncomed Pharmaceuticals Inc : Oncomed Pharmaceuticals announces Bayer terminates its option to license vantictumab or ipafricept . Oncomed - Bayer Pharma notified co of decision not to exercise option to license WNT pathway inhibitors vantictumab, ipafricept for strategic reasons . Oncomed - Effective June 2017, co to retain worldwide development & commercialization rights to vantictumab, ipafricept, WNT pathway biologics . Oncomed Pharmaceuticals Inc - small molecule program under companies' collaboration continues without change .Oncomed - will be conducting internal portfolio review and prioritization to determine next steps for all programs, including vantictumab, ipafricept.  Full Article

Monsanto Q2 earnings per share $3.09
Wednesday, 5 Apr 2017 08:00am EDT 

Monsanto Co : Monsanto continues return to growth in fiscal year 2017 with strong second quarter and first half results; updates outlook for full year eps to high end of guidance range . Q4 sales $5.1 billion versus $4.5 billion . Q2 earnings per share $3.19 from continuing operations . Q2 earnings per share $3.09 . Q2 earnings per share view $2.82 -- Thomson Reuters I/B/E/S . Monsanto - full year 2017 eps guidance now expected to be at high end of range of $3.95 to $4.44 on an as-reported basis and $4.50 to $4.90 on an ongoing basis . Monsanto Co - "continue to expect growth in global corn platform, led by price increases in local currency in south america" . Monsanto Co says for Q3, expects as-reported earnings per share to be roughly flat due to absence of argentine-related tax matters call-out of $0.50 /share . Fy2017 earnings per share view $4.75 -- Thomson Reuters I/B/E/S . Monsanto Co - qtrly total seeds and genomics sales $4,186 million versus $3,817 million . Monsanto Co says continues to expect seed and genomics segment gross profit to increase mid-single digits as a percent year-over-year in 2017 . Monsanto Co says within its AG productivity segment, gross profit is still expected to be in range of $850 to $950 million in 2017 . Monsanto-Overall operating expenses in 2017, excluding pending bayer deal-related costs & restructuring charges, expected to increase slightly.  Full Article

Crispr and Casebia announce commercial license agreement with Maxcyte
Tuesday, 14 Mar 2017 07:00am EDT 

Crispr Therapeutics Ag : Crispr Therapeutics and Casebia Therapeutics announce commercial license agreement with Maxcyte . Maxcyte will supply systems Co and Casebia as part of license agreement and will receive upfront, milestone, and sales-based payments . Says commercial license builds on an existing research and clinical licensing agreement for select disease areas .Crispr, Casebia will obtain non-exclusive commercial-use rights to Maxcyte's cell engineering platform to develop crispr/CAS9-based therapies for SCID.  Full Article

Bayer places Covestro shares at 66.50 euros apiece
Wednesday, 1 Mar 2017 02:05am EST 

Bayer : Says has reduced its holding in Covestro from 64.2 percent to 53.3 percent . Says Places Covestro shares at 66.50 euros apiece . Says still expects a mid-single-digit percentage increase in core earnings per share from continuing operations in 2017 . Says Covestro will continue to be fully consolidated in Bayer’s statement of financial position .  Full Article

FTC approves final order settling charges for Boehringer Ingelheim’s asset swap with Sanofi
Friday, 24 Feb 2017 01:47pm EST 

U.S. Federal Trade Commission (FTC) :U.S. FTC - Approved final order settling charges that Boehringer Ingelheim’s $13.53 billion asset swap with Sanofi would likely be anticompetitive.  Full Article

Dow Chemical updates on patent dispute with Bayer
Thursday, 9 Feb 2017 09:38am EST 

Dow Chemical Co : Dow Chemical - In January 2017, the USPTO issued final office actions for two of the patents asserted in a case, including the ‘962 patent . Dow Chemical - USPTO rejected all relevant claims related to a patents dispute with Bayer, based on the doctrine against double-patenting . Dow Chemical - Re-examination proceedings with respect to other two patents remain pending, although co anticipates that USPTO will likewise invalidate those patents . Dow Chemical - Although Bayer may appeal these decisions, co believes USPTO final office actions will provide a strong basis to vacate the arbitral award .Dow Chemical - As part of the co’s review of the arbitral award, co assessed the legal and factual circumstances of the case.  Full Article

Regeneron says price increases unrelated from innovation will be pushed back on
Thursday, 9 Feb 2017 09:00am EST 

Regeneron Pharmaceuticals Inc - : Regeneron CEO: "As we further diversify our product related revenue stream, we do not plan to provide eylea guidance after 2017" . Regeneron CEO says Amgen's asserted patent claims on repatha are invalid and we look forward to pursuing our appeal over the coming months: conf call . Regeneron's Bob Terifay says Eylea will continue for co over the years to come . Regeneron: Eylea sales growth has slowed reflecting normal market dynamics for the product that has been around for over 5 yrs with no price hike since launch . Regeneron CEO says changes in pharmaceutical drug pricing will need congressional action . Regeneron CEO "Price increases that are unrelated or uncoupled from innovation will be pushed back on" . Regeneron CEO: Constant price increases & magnitude of them are reflection of tone deafness on those taking hikes & complexities about how rebates work . Regeneron CEO: "There is an opportunity to come up with more responsible pricing", in relation to rheumatoid arthritis drug, sarilumab . Regeneron CEO: "Pharma is running around saying the middleman (PBM) is taking too much; the middleman says prices are too high and patients are wondering what is really going on" . Regeneron CEO: "price increases are nice but if you cannot get them you better be able to innovate and that is our sweet spot" Further company coverage: [AMGN.O] ((bangalore.newsroom@thomsonreuters.com;)).  Full Article

Bayer says Regorafenib granted priority review in Japan
Friday, 20 Jan 2017 02:02am EST 

Bayer AG : Bayer says Regorafenib from Bayer granted priority review in Japan for the second-line treatment of liver cancer Further company coverage: [BAYGn.DE] ((frankfurt.newsroom@thomsonreuters.com; +49 69 7565 1270;)).  Full Article

Bayer, Leica Biosystems to develop companion diagnostic test for cancer patients
Wednesday, 21 Dec 2016 02:38am EST 

Bayer AG : Says develops companion diagnostic test for cancer patients together with Leica Biosystems . The partners will use Leica Biosystems expertise in assay development, regulatory approval and commercialization of companion diagnostic tests .Financial terms of the agreement were not disclosed.  Full Article

More From Around the Web

Photo

M&A code names can be a warning in themselves

LONDON (Reuters Breakingviews) - The code names bankers and companies attach to their mergers and acquisitions can reveal much about their own hubris. Last year, according to a study by data company IntraLinks, the most popular secret deal names included Project Diamond and Project Falcon – even though most mergers fall short of their potential. Breakingviews has taken some actual code names from the past year, and applied them to deals that seem particularly fitting.